Jim Jones, Darin J Correll, Sandra M Lechner, Ina Jazic, Xiaopeng Miao, David Shaw, Christopher Simard, Jeremiah D Osteen, Brian Hare, Alina Beaton, Todd Bertoch, Asokumar Buvanendran, Ashraf S Habib, Lois J Pizzi, Richard A Pollak, Scott G Weiner, Carmen Bozic, Paul Negulescu, Paul F White
BACKGROUND: The NaV 1.8 voltage-gated sodium channel, expressed in peripheral nociceptive neurons, plays a role in transmitting nociceptive signals. The effect of VX-548, an oral, highly selective inhibitor of NaV 1.8, on control of acute pain is being studied. METHODS: After establishing the selectivity of VX-548 for NaV 1.8 inhibition in vitro, we conducted two phase 2 trials involving participants with acute pain after abdominoplasty or bunionectomy. In the abdominoplasty trial, participants were randomly assigned in a 1:1:1:1 ratio to receive one of the following over a 48-hour period: a 100-mg oral loading dose of VX-548, followed by a 50-mg maintenance dose every 12 hours (the high-dose group); a 60-mg loading dose of VX-548, followed by a 30-mg maintenance dose every 12 hours (the middle-dose group); hydrocodone bitartrate-acetaminophen (5 mg of hydrocodone bitartrate and 325 mg of acetaminophen every 6 hours); or oral placebo every 6 hours...
August 3, 2023: New England Journal of Medicine